United Therapeutics Corporation
US ˙ NasdaqGS ˙ US91307C1027

SecurityUTHR / United Therapeutics Corporation
InstitutionTobam
Latest Disclosed Ownership8,915 shares
Latest Disclosed Value $ 5,286
Tobam reports 9.56% decrease in ownership of UTHR / United Therapeutics Corporation

On May 12, 2026 - Tobam filed a 13F-HR form disclosing ownership of 8,915 shares of United Therapeutics Corporation (US:UTHR) valued at $5,286,417 USD as of March 31, 2026. The entity filed a previous 13F-HR on March 2, 2026 disclosing 9,857 shares of United Therapeutics Corporation. This represents a change in shares of -9.56% during the quarter. The current value of the position is $4,898,525 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F UNITED THERAPEUTICS COM 91307C102 8,915 -942 -9.56 5 25.00 1.3759
2026-03-02 2025-12-31 13F UNITED THERAPEUTICS COM 91307C102 9,857 2,211 28.92 5 33.33 1.1796
2025-11-07 2025-09-30 13F UNITED THERAPEUTICS COM 91307C102 7,646 4,953 183.92 3 1.1612
2025-08-08 2025-06-30 13F UNITED THERAPEUTICS COM 91307C102 2,693 -3,695 -57.84 1 -100.00 0.3021
2025-04-16 2025-03-31 13F UNITED THERAPEUTICS COM 91307C102 6,388 -11,834 -64.94 2 -83.33 0.8415
2025-01-28 2024-12-31 13F UNITED THERAPEUTICS COM 91307C102 18,222 -19,719 -51.97 6 -53.85 1.9618
2024-10-09 2024-09-30 13F UNITED THERAPEUTICS COM 91307C102 37,941 -18,317 -32.56 14 -23.53 2.4792
2024-08-01 2024-06-30 13F/A-1 UNITED THERAPEUTICS COM 91307C102 56,258 -52,389 -48.22 18 -29.17 2.8098
2024-07-29 2024-06-30 13F UNITED THERAPEUTICS COM 91307C102 56,258 -52,389 18 2.8098
2024-05-02 2024-03-31 13F UNITED THERAPEUTICS COM 91307C102 108,647 -5,110 -4.49 25 -4.00 2.2367
2024-01-26 2023-12-31 13F UNITED THERAPEUTICS COM 91307C102 113,757 -31,663 -21.77 25 -21.87 2.1874
2023-10-31 2023-09-30 13F UNITED THERAPEUTICS COM 91307C102 145,420 -3,073 -2.07 33 0.00 2.6359
2023-07-31 2023-06-30 13F UNITED THERAPEUTICS COM 91307C102 148,493 -21,430 -12.61 33 -15.79 2.4717
2023-05-03 2023-03-31 13F UNITED THERAPEUTICS COM 91307C102 169,923 60,639 55.49 38 26.67 2.5082
2023-02-02 2022-12-31 13F UNITED THERAPEUTICS COM 91307C102 109,284 67,767 163.23 30 -99.65 2.0119
2022-11-02 2022-09-30 13F UNITED THERAPEUTICS COM 91307C102 41,517 37,750 1,002.12 8,693 878.94 0.6076
2022-08-02 2022-06-30 13F UNITED THERAPEUTICS COM 91307C102 3,767 3,767 888 0.0556
2019-05-15 2019-03-31 13F UNITED THERAPEUTICS COM 91307C102 0 -17,080 -100.00 0 -100.00
2019-02-11 2018-12-31 13F UNITED THERAPEUTICS COM 91307C102 17,080 -18,915 -52.55 1,860 -59.59 0.0895
2018-11-08 2018-09-30 13F UNITED THERAPEUTICS COM 91307C102 35,995 -8,157 -18.47 4,603 -7.87 0.1964
2018-08-03 2018-06-30 13F UNITED THERAPEUTICS COM 91307C102 44,152 8,874 25.15 4,996 26.03 0.2057
2018-05-14 2018-03-31 13F UNITED THERAPEUTICS COM 91307C102 35,278 3,035 9.41 3,964 -16.90 0.1628
2018-02-14 2017-12-31 13F UNITED THERAPEUTICS COM 91307C102 32,243 -35,156 -52.16 4,770 -39.60 0.2064
2017-11-14 2017-09-30 13F UNITED THERAPEUTICS COM 91307C102 67,399 -356 -0.53 7,898 -10.15 0.2984
2017-08-08 2017-06-30 13F UNITED THERAPEUTICS COM 91307C102 67,755 8,820 14.97 8,790 10.18 0.3283
2017-05-09 2017-03-31 13F UNITED THERAPEUTICS COM 91307C102 58,935 -14,528 -19.78 7,978 -24.28 0.3080
2017-02-15 2016-12-31 13F UNITED THERAPEUTICS COM 91307C102 73,463 -53,984 -42.36 10,536 -29.99 0.4291
2016-12-01 2016-09-30 13F UNITED THERAPEUTICS COM 91307C102 127,447 59,275 86.95 15,049 108.41 0.5418
2016-08-25 2016-06-30 13F UNITED THERAPEUTICS COM 91307C102 68,172 -31,239 -31.42 7,221 -34.81 0.2890
2016-05-10 2016-03-31 13F UNITED THERAPEUTICS COM 91307C102 99,411 -54,648 -35.47 11,077 -54.09 0.4365
2016-02-16 2015-12-31 13F UNITED THERAPEUTICS COM 91307C102 154,059 -22,314 -12.65 24,128 4.24 1.0428
2015-11-20 2015-09-30 13F UNITED THERAPEUTICS COM 91307C102 176,373 -71,693 -28.90 23,147 -46.36 0.9035
2015-08-14 2015-06-30 13F UNITED THERAPEUTICS COM 91307C102 248,066 248,066 43,150 1.5739
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.